what if we could regulate genes, not just discover them? what if we could treat disease at their genetic source? what if we could integrate multiple disciplines to develop breakthrough medicines? what if you could be a part of a passionate team committed to the patients we serve? we can. we will. we are. join us. we are here to develop new medicines to deliver a new future for patients and their families by transforming gene regulation in disease. a fulcrum is defined as the point on which a lever rests, balances and pivots. fulcrum therapeutics is intervening in gene regulatory mechanisms to unlock the information contained in the human genome. the fulcrum product engine is dedicated to bringing balance to the genetic on and off switches in disease. our approach the sequencing of the human genome has provided incredible insight into disease biology, yet the richness of biology comes from the dynamic on and off switches that control the genome – gene regulation. the fulcrum product eng
Company profile
Ticker
FULC
Exchange
Website
CEO
Robert J. Gould
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Fulcrum Therapeutics Securities Corp. ...
IRS number
474839948
FULC stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
27 Feb 24
S-3
Shelf registration
27 Feb 24
10-K
2023 FY
Annual report
27 Feb 24
8-K
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results
27 Feb 24
10-Q
2023 Q3
Quarterly report
7 Nov 23
8-K
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results
7 Nov 23
8-K
Departure of Directors or Certain Officers
2 Oct 23
8-K
Regulation FD Disclosure
22 Aug 23
10-Q
2023 Q1
Quarterly report
3 Aug 23
8-K
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results
3 Aug 23
Transcripts
FULC
Earnings call transcript
2023 Q4
27 Feb 24
FULC
Earnings call transcript
2023 Q3
7 Nov 23
FULC
Earnings call transcript
2023 Q2
3 Aug 23
FULC
Earnings call transcript
2023 Q1
15 May 23
FULC
Earnings call transcript
2022 Q4
9 Mar 23
FULC
Earnings call transcript
2022 Q3
12 Nov 22
FULC
Earnings call transcript
2022 Q2
11 Aug 22
FULC
Earnings call transcript
2022 Q1
9 May 22
FULC
Earnings call transcript
2021 Q4
3 Mar 22
FULC
Earnings call transcript
2021 Q3
6 Nov 21
Latest ownership filings
4
Patrick Taylor Horn
20 Mar 24
3
Patrick Taylor Horn
20 Mar 24
4
Greg Tourangeau
8 Mar 24
144
Notice of proposed sale of securities
8 Mar 24
4
Alex Sapir
5 Mar 24
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
14 Feb 24
SC 13G/A
Third Rock Ventures III, L.P.
14 Feb 24
SC 13G/A
RTW INVESTMENTS, LP
14 Feb 24
SC 13G/A
SUVRETTA CAPITAL MANAGEMENT, LLC
13 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 31.17 mm | 31.17 mm | 31.17 mm | 31.17 mm | 31.17 mm | 31.17 mm |
Cash burn (monthly) | 1.30 mm | 5.07 mm | 9.15 mm | 9.22 mm | 7.64 mm | 7.29 mm |
Cash used (since last report) | 7.75 mm | 30.34 mm | 54.72 mm | 55.16 mm | 45.68 mm | 43.63 mm |
Cash remaining | 23.42 mm | 830.39 k | -23.55 mm | -23.99 mm | -14.51 mm | -12.45 mm |
Runway (months of cash) | 18.1 | 0.2 | -2.6 | -2.6 | -1.9 | -1.7 |
Institutional ownership, Q3 2023
99.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 85 |
Opened positions | 15 |
Closed positions | 23 |
Increased positions | 17 |
Reduced positions | 26 |
13F shares | Current |
---|---|
Total value | 248.16 bn |
Total shares | 61.89 mm |
Total puts | 183.00 k |
Total calls | 670.10 k |
Total put/call ratio | 0.3 |
Largest owners | Shares | Value |
---|---|---|
Ra Capital Management | 11.61 mm | $51.55 bn |
FMR | 5.98 mm | $26.53 bn |
RTW Investments | 5.82 mm | $25.84 bn |
Suvretta Capital Management | 5.72 mm | $25.39 bn |
Cowen And | 4.31 mm | $19.13 bn |
Vanguard | 2.64 mm | $11.74 bn |
Adage Capital Partners GP, L.L.C. | 2.41 mm | $10.68 bn |
Third Rock Ventures III | 2.34 mm | $0.00 |
TRV GP Iv | 2.34 mm | $10.40 bn |
GSK GSK | 1.79 mm | $38.82 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
18 Mar 24 | Horn Patrick Taylor | Stock Option Common Stock | Grant | Acquire A | No | No | 10.12 | 400,000 | 4.05 mm | 400,000 |
8 Mar 24 | Greg Tourangeau | Common Stock | Sell | Dispose S | No | No | 11.7155 | 4,884 | 57.22 k | 11,807 |
4 Mar 24 | Sapir Alex | Common Stock | Buy | Acquire P | No | No | 11.3475 | 43,360 | 492.03 k | 43,360 |
26 Jan 24 | Curtis Gale Oltmans | Stock Option Common Stock | Grant | Acquire A | No | No | 6.95 | 150,000 | 1.04 mm | 150,000 |
News
RBC Capital Initiates Coverage On Fulcrum Therapeutics with Outperform Rating, Announces Price Target of $14
13 Mar 24
Why United Natural Foods Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
6 Mar 24
Box Reports Upbeat Earnings, Joins American Public Education, Wave Life Sciences And Other Big Stocks Moving Higher On Wednesday
6 Mar 24
Deep Dive Into Fulcrum Therapeutics Stock: Analyst Perspectives (4 Ratings)
28 Feb 24
HC Wainwright & Co. Maintains Buy on Fulcrum Therapeutics, Raises Price Target to $17
28 Feb 24
Press releases
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
22 Mar 24
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
8 Mar 24
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023
27 Feb 24
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on Tuesday, February 27, 2024, at 8:00 a.m. ET
20 Feb 24